Scientific discovery by St. Jude group could lead to new pathway for cancer treatment and understanding of ALS.
The 2018 annual meeting of the American Society of Hematology will include research from St. Jude that stretches from the laboratory to the clinic.
St. Jude scientists and clinicians highlighted at the annual American Society of Hematology in San Diego. Read the latest.
The Public Resource of Patient-derived and Expanded Leukemias (PROPEL) offers patient-derived xenograft samples free of charge for researchers worldwide.
A surprising mechanism that might explain how the Hippo signaling pathway promotes solid tumor growth.
Common genetic variations may help find female childhood cancer survivors at increased risk of breast cancer and who are candidates for stepped up screening.
Children with ALL gain weight during treatment, and researchers suggest that early interventions should be considered.
Read how a discovery in bacteria in the 1980s led to a promising new class of compounds for treatment of PKAN, a progressive neurodegenerative disease.
Scientists have a new strategy to enhance the anti-cancer immune response and slow tumor growth. The goal is to reprogram macrophages to eliminate tumor cells.
Presentations outline data from Genomes for Kids study, proving clinical utility of multi-platform genome sequencing for pediatric precision oncology.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Courageous patients. Resolute doctors. Caring staff. Inventive scientists. Their voices come alive in Promise magazine.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.